PRIMARY STUDY

L/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease

Key Findings:  This study evaluated the efficacy of cilnidipine versus amlodipine in patients with chronic kidney disease. In the cilnidipine group the percent of reduction in urinary albumin to creatinine ratio and liver-type fatty acid binding protein (L-FABP) was significantly greater than in the amlodipine group, independent of percent of blood pressures reduction.